Evaluating treatments for elderly patients with lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to collect real-life data on patients aged 70 and older who are receiving first-line treatment for non-small-cell lung cancer. It will characterize participants based on geriatric, biological, and cancer-related factors, while also documenting treatment modalities and their efficacy, safety, and impact on quality of life. Participants will be monitored according to standard clinical practices, with regular check-ups and assessments to evaluate their treatment outcomes. Additionally, specific sub-cohorts will be formed to explore uniform treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient ≥70 years
* Non-small-cell lung cancer for which the multidisciplinary consultation required systemic treatment regardless of Tumor-Node-Metastasis (TNM) stage
* Patient naïve to systemic anticancer treatment for bronchial neoplasia
* Patient covered by social security
* Patient eligible for systemic treatment
* Systemic treatment with marketing authorization in the indication, available in routine care early access or compassionate access.
* Patient able to understand the protocol
* Patient not opposed to the collection of data concerning him/her
* Signature of study consent form.

Exclusion Criteria:

* Patients under guardians or curators
* Patient not under the care of the investigating center and not monitored by the investigating center
* Patient already treated with systemic therapy for NSCLC

Where it's running

• CH du Pays d Aix
  Aix-en-Provence, France Recruiting
• Hôpital Henri Duffaut
  Avignon, France Recruiting
• Institut du Cancer d'Avignon
  Avignon, France Recruiting
• Oncologie Thoracique Hôpital Morvan
  Brest, France Recruiting
• CH Métropole-Savoie
  Chambéry, France Recruiting
• Centre Hospitalier du Cotentin
  Cherbourg, France Recruiting

Study contacts

• Study coordinator: Romain CORRE, Medical Doctor
• Email: romain.corre@ch-cornouaille.fr
• Phone: +330298526404

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Does the time of day for PD-1/PD-L1 therapy affect response in NSCLC and HNSCC

  In people with advanced NSCLC or resectable head and neck cancer, this study tests whether receiving PD-1/PD-L1 therapy in the morning versus the afternoon changes treatment outcomes.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07630168

• Romiplostim N01 plus ATRA for persistent chemotherapy-induced low platelets after remission from gynecologic, breast, or lung cancer

  This trial tests whether adding ATRA to Romiplostim N01 helps people keep a safe platelet count after finishing chemotherapy for certain cancers.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07586826

• 3-D virtual resection to predict lung function after VATS anatomical lung surgery

  The study will test whether a 3-D virtual resection from thin-slice CT scans can better predict lung function after VATS lobectomy or segmentectomy for people with non-small cell lung cancer.

  Recruiting National Taiwan University Hospital · Taipei · NCT07436598

• Precise Exercise Regimen for Cancer Care: a small pilot in stage II/III NSCLC

  This pilot tests the PERCC exercise program to see if it’s feasible for adults with stage II–III non-small cell lung cancer who are planned for neoadjuvant therapy and surgery.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07412041

• PF-08634404 plus chemotherapy versus pembrolizumab-based chemotherapy for advanced non-small cell lung cancer

  This will test whether PF-08634404 combined with chemotherapy works better than pembrolizumab plus chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer who have not received prior treatment for their advanced disease.

  Recruiting at 464 sites Phase 3 Pfizer · Bullhead City, Arizona and 483 other locations · NCT07222566

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.